前列腺癌骨转移机制和骨靶向药物研究进展

doi:10.11904/j.issn.1002-3070.2023.03.009

摘要/Abstract

摘要： 骨是前列腺癌最常见的晚期转移部位,骨微环境和前列腺癌中多种细胞因子如核因子-κB受体活化因子配体(Receptor activator of NF-κB ligand,RANKL)、趋化因子家族、整合素等通过复杂的相互作用机制参与了前列腺癌骨转移。多种骨靶向药物如二磷酸盐、地诺单抗和放疗药物如镭-223被批准用于预防和治疗因前列腺癌骨转移引起的骨骼相关事件(Skeletal-related events,SREs)。本文对前列腺癌骨转移的生物学机制和骨靶向药物研究进展进行综述。

关键词: 前列腺癌, 骨转移机制, 骨靶向药物

Abstract: Bone is the most common metastatic site of advanced prostate cancer(PCa).Various cytokines such as receptor activator of nuclear factor-κB ligand(RANKL),chemokine families,integrins,etc.in the bone microenvironment and PCa,are involved in bone metastasis of PCa through complex interaction mechanisms.Multiple bone-targeted drugs such as disphosphonate,denosumab,and radiotherapy drugs such as radium-223 have been approved for prevention and treatment of skeletal related events(SREs)caused by PCa bone metastases.This article reviews the biological mechanisms of prostate cancer bone metastasis and the research progression of bone-targeted drugs.

Key words: Prostate cancer, Mechanism of bone metastatic, Bone-targeted drugs

中图分类号:

R737.25

韩焱崧, 任明华. 前列腺癌骨转移机制和骨靶向药物研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 252-256.

HAN Yansong, REN Minghua. Research progression in the mechanism of bone metastasis and bone-targeted drugs in prostate cancer[J]. Journal of Practical Oncology, 2023, 37(3): 252-256.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.03.009

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I3/252

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Nuhn P,De Bono JS,Fizazi K,et al.Update on systemic prostate cancer therapies:management of metastatic castration-resistant prostate cancer in the era of precision oncology[J].Eur Urol,2019,75(1):88-99.
3 Thalmann GN,Karkampouna S.Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer[J].Cancer Lett,2022,530:156-169.
4 Singh DK,Patel VG,Oh WK,et al.Prostate cancer dormancy and reactivation in bone marrow[J].J Clin Med,2021,10(12):2648.
5 Gartrell BA,Coleman R,Efstathiou E,et al.Metastatic prostate cancer and the bone:significance and therapeutic options[J].Eur Urol,2015,68(5):850-858.
6 Deng X,He G,Liu J,et al.Recent advances in bone-targeted therapies of metastatic prostate cancer[J].Cancer Treat Rev,2014,40(6):730-738.
7 Baci D,Bruno A,Cascini C,et al.Acetyl-L-Carnitine downregulates invasion(CXCR4/CXCL12,MMP-9)and angiogenesis(VEGF,CXCL8)pathways in prostate cancer cells:rationale for prevention and interception strategies[J].J Exp Clin Cancer Res,2019,38(1):464.
8 Midavaine E,Cote J,Sarret P.The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers[J].Cancer Metastasis Rev,2021,40(2):427-445.
9 Cioni B,Nevedomskaya E,Melis MHM,et al.Loss of androgen receptor signaling in prostate cancer-associated fibroblasts(CAFs)promotes CCL2-and CXCL8-mediated cancer cell migration[J].Mol Oncol,2018,12(8):1308-1323.
10 Siddiqui JA,Seshacharyulu P,Muniyan S,et al.GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation[J].Bone Res,2022,10(1):6.
11 Li Y,He Y,Butler W,et al.Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer[J].Sci Transl Med,2019,11(521):11-44.
12 Singh R,Kapur N,Mir H,et al.CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering[J].Oncotarget,2016,7(6):7343-7353.
13 Connell B,Kopach P,Ren W,et al.Aberrant integrin αv and α5 expression in prostate adenocarcinomas and bone-metastases is consistent with a bone-colonizing phenotype[J].Transl Androl Urol,2020,9(4):1630-1638.
14 Quayle L,Ottewell PD,Holen I.Bone metastasis:molecular mechanisms implicated in tumour cell dormancy in breast and prostate cancer[J].Curr Cancer Drug Targets,2015,15(6):469-480.
15 Yumoto K,Eber MR,Wang J,et al.Axl is required for TGF-β2-induced dormancy of prostate cancer cells in the bone marrow[J].Sci Rep,2016,6:36520.
16 Kobayashi A,Okuda H,Xing F,et al.Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone[J].J Exp Med,2011,208(13):2641-2655.
17 Park M,Cho YJ,Kim B,et al.RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway[J].Sci Rep,2021,11(1):12186.
18 Ren D,Dai Y,Yang Q,et al.Wnt5a induces and maintains prostate cancer cells dormancy in bone[J].J Exp Med,2019,216(2):428-449.
19 Zhang X.Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer[J].Cancer Commun(Lond),2019,39(1):76.
20 Liu Q,Li A,Tian Y,et al.The CXCL8-CXCR1/2 pathways in cancer[J].Cytokine Growth Factor Rev,2016,31:61-71.
21 Danilucci TM,Santos PK,Pachane BC,et al.Recombinant RGD-disintegrin DisBa-01 blocks integrin αvβ3 and impairs VEGF signaling in endothelial cells[J].Cell Commun Signal,2019,17(1):27.
22 Decker AM,Jung Y,Cackowski FC,et al.Sympathetic signaling reactivates quiescent disseminated prostate cancer cells in the bone marrow[J].Mol Cancer Res,2017,15(12):1644-1655.
23 Wu AC,He Y,Broomfield A,et al.CD169(+)macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer[J].J Pathol,2016,239(2):218-230.
24 Lin SC,Lee YC,Yu G,et al.Endothelial-to-osteoblast conversion generates osteoblastic metastasis of prostate cancer[J].Dev Cell,2017,41(5):467-480.
25 Zhang Y,Liang J,Liu P,et al.The RANK/RANKL/OPG system and tumor bone metastasis:potential mechanisms and therapeutic strategies[J].Front Endocrinol(Lausanne),2022,13:1063815.
26 Zhang B,Li Y,Wu Q,et al.Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer[J].Nat Commun,2021,12(1):1714.
27 Sun CY,Mi YY,Ge SY,et al.Tumor-and osteoblast-derived periostin in prostate cancer bone metastases[J].Front Oncol,2022,11:795712.
28 Saad F,Gleason D,Murray R,et al.A randomized,placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J].Natl Cancer Inst,2002,94:1458-1468.
29 Finianos A,Aragon-Ching JB.Zoledronic acid for the treatment of prostate cancer[J].Expert Opin Pharmacother,2019,20(6):657-666.
30 Landgraf M,Lahr CA,Sanchez-Herrero A,et al.Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo[J].Bone Res,2019,7:31.
31 Hegemann M,Bedke J,Stenzl A,et al.Denosumab treatment in the management of patients with advanced prostate cancer:clinical evidence and experience[J].Ther Adv Urol,2017,9(3-4):81-88.
32 Zhang N,Zhang ZK,Yu Y,et al.Pros and cons of denosumab treatment for osteoporosis and implication for RANKL aptamer therapy[J].Front Cell Dev Biol,2020,8:325.
33 Jakob T,Tesfamariam YM,Macherey S,et al.Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases:a network meta-analysis[J].Cochrane Database Syst Rev,2020,12(12):CD013020.
34 Fizazi K,Carducci M,Smith M,et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised,double-blind study[J].Lancet,2011,377(9768):813-822.
35 van der Zande K,Oyen WJG,Zwart W,et al.Radium-223 treatment of patients with metastatic castration resistant prostate cancer:biomarkers for stratification and response evaluation[J].Cancers(Basel),2021,13(17):4346.
36 Parker C,Nilsson S,Heinrich D,et al.Alpha emitter radium-223 and survival in metastatic prostate cancer[J].N Engl J Med,2013,369(3):213-223.
37 Gomez Rivas J,Carrion DM,Alvarez-Maestro M,et al.Bone-targeted therapy in castration-resistant prostate cancer:where do we stand?[J].Minerva Urol Nefrol,2019,71(5):445-456.
38 Hu Z,Tian Y,Li W,et al.The efficacy and safety of zoledronic acid and strontium-89 in treating non-small cell lung cancer:a systematic review and meta-analysis of randomized controlled trials[J].Support Care Cancer,2020,(7):3291-3301.
39 Baba K,Kaida H,Hattori C,et al.Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases[J].Hell J Nucl Med,2018,21(1):15-23.
40 Murray I,Du Y.Systemic radiotherapy of bone metastases with radionuclides[J].Clin Oncol(R Coll Radiol),2021,33(2):98-105.
41 Fioramonti M,Santini D,Iuliani M,et al.Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions[J].Oncotarget,2017,8(12):20113-20121.
42 Schoffski P,Gordon M,Smith DC,et al.Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours[J].Eur J Cancer,2017,86:296-304.
43 Smith DC,Daignault-Newton S,Grivas P,et al.Efficacy and effect of cabozantinib on bone metastases in treatment-naive castration-resistant prostate cancer[J].Clin Genitourin Cancer,2020,18(4):332-339.
44 Paindelli C,Casarin S,Wang F,et al.Enhancing 223Ra treatment efficacy by anti-β1 integrin targeting[J].J Nucl Med,2022,63(7):1039-1045.
45 Hill EE,Kim JK,Jung Y,et al.Integrin alphaV beta3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis[J].J Cell Biochem,2018,119(10):8074-8083.

[1]	周孟孟, 徐文超, 俞浩. 1990—2019年江苏省男性前列腺癌疾病负担分析[J]. 实用肿瘤学杂志, 2023, 37(1): 1-5.
[2]	李浩, 滕立臣. 外泌体环状RNA在前列腺癌中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(1): 92-96.
[3]	高科, 任明华. 去势抵抗性前列腺癌的药物治疗现状[J]. 实用肿瘤学杂志, 2021, 35(4): 376-379.
[4]	苗鹏程, 康印东, 李富东, 孟冬冬, 王东星, 常德辉. lncRNA SNHGs在前列腺癌发生发展中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 446-450.
[5]	姜涛, 张旭. 孤儿核受体在前列腺癌中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 377-380.
[6]	毛高才，朱其聪，沈宏峰，涂瑞沙，闫庆国. 膀胱与前列腺交界处多向分化癌3例临床病理分析[J]. 实用肿瘤学杂志, 2016, 30(6): 538-542.
[7]	牛德方，崔岩，综述，陈辉，审校. CyclinD1表达与泌尿系统肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2016, 30(6): 547-550.
[8]	赵锐, 孔祥波, 金宁, 张刚. siRNA干扰cytohesins导致前列腺癌细胞中IGFR信号减低[J]. 实用肿瘤学杂志, 2011, 25(4): 361-364.
[9]	李洁冰, 张艳华, 程文, 张本平. 三维能量多普勒对前列腺癌分化程度研究[J]. 实用肿瘤学杂志, 2010, 24(5): 413-414.
[10]	吴迪综述, 张艳华审校. 经直肠三维超声在前列腺癌诊断中的应用进展[J]. 实用肿瘤学杂志, 2009, 23(5): 496-500.
[11]	乔振奎, 徐万海, 王晓民, 苏宇. 白藜芦醇对人前列腺癌PC-3细胞株VEGF的表达及细胞增殖的影响^△[J]. 实用肿瘤学杂志, 2009, 23(3): 242-24.
[12]	朱芳. Survivin蛋白在前列腺癌组织中表达及临床意义的meta分析[J]. 实用肿瘤学杂志, 2007, 21(05): 453-456.
[13]	何晓燕;骆利康;郑俊. AMACR在前列腺癌诊断与鉴别诊断中的应用[J]. 实用肿瘤学杂志, 2007, 21(04): 342-343.
[14]	赵维明;徐勇;王燕铭;程兆康;张素爱;于琦;孔德领. 壳聚糖纳米粒介导的CD基因对前列腺癌的体外杀伤作用[J]. 实用肿瘤学杂志, 2006, 20(06): 513-516,.
[15]	黄赖机;张秀萍;李健;邓瑾;P.LABAT;I.NATALIE. 三维适形放疗技术在局限性前列腺癌治疗中的应用[J]. 实用肿瘤学杂志, 2005, 19(05): 374-376.